Intention notice: 2599q riluzol

Description du marché

Sykehusinnkjøp HF intends, on behalf of the four regional health authorities, to enter into a framework agreement with Teva Norway AS from and including 1 May 2025 on the delivery of the medicine Riluzol Actavis soluble tablets for the treatment of the disease amyotrophic lateral sclerosis (ALS). ALS is a rare progressive nerve disease that causes gradual wastage of motor nerves in the cerebral cortch and spinal cord. There is no treatment that can cure the disease, but there is one registered medicine that can give prolonged survival for this patient group. Reasons for awarding the contract without a competition notice: The manufacturer of the original medicine (Sanofi) notified Sykehusinnkjøp HF in April 2024 that they will stop the production of Rilutek tablets (riluzol) starting May 2 024.On this occasion Sykehusinnkjøp has undertaken market surveys and noted that there is only one tenderer with marketing authorisation in the EU/EEA for medicines with the active ingredient riluzole tablets that are willing to assist with deliveries to norwegian Market. The contracting authority therefore believes that it is necessary to enter into a contract without a competition in accordance with the procurement regulations § 13-4 first section, letter b no. 2. The framework agreement is planned to be signed 10 days after publication of the intention notice. The contract has an estimated annual value of NOK 3,400,000 excluding VAT and a maximum value of NOK 3,400,000. NOK 13,600,000 excluding VAT. The framework agreement will be valid for two years, with an option for an extension for up to 24 months.

Pouvoir adjudicateur